Utility of physiologically based pharmacokinetic (PBPK) modeling in oncology drug development and its accuracy: a systematic review
Physiologically based pharmacokinetic (PBPK) modeling, a mathematical modeling approach which uses a pharmacokinetic model to mimick human physiology to predict drug concentration–time profiles, has been used for the discover and development of drugs in various fields, including oncology, since 2000. There have been a few general review articles on the utilization of PBPK in the development of oncology drugs, but these do not include an evaluation of model prediction accuracy. We therefore conducted a systematic review to define the accuracy of PBPK model prediction and its utility throughout all the developmental phases of oncology drugs.
A systematic search was performed in the PubMed, PubMed Central and Cochrane Library databases from 1980 to February 2017 for articles (1) written in English, (2) focused on oncology or antineoplastic or anticancer drugs, tumor or cancer or anticancer drugs listed in the U.S. National Institutes of Health and (3) involving a PBPK model. The absolute-average-folding-errors (AAFEs) of the area under the curve (AUC) between predicted and observed values in each article were calculated to assess model prediction accuracy.
Of the 2341 articles initially identified by our search of the databases, 40 were included in the review analysis. These articles reported on six types of studies, i.e. in vivo (n = 4), first-in-human (n = 5), phase II/III clinical trials (n = 9), organ impairment (n = 3), pediatrics (n = 4) and drug–drug interactions (n = 15). AAFEs of the predicted AUC for all groups of studies were within 1.3-fold of each other despite variations in experimental methodologies.
PBPK modeling is a potential tool which can be effectively applied throughout all phases of oncology drug development. The number of experimental animals and human participants enrolled in the studies can be reduced using PBPK modeling and PBPK-population-PK modeling. The limited number of publications of unsuccessful model application to date may contribute to bias toward the usefulness of modeling.
KeywordsPhysiologically based pharmacokinetic modeling Oncology drug development Systematic review Accuracy
Contribution of author statement
TS was responsible for data collection, selection of the published articles, data analysis and data interpretation and prepared the draft manuscript. KN and JK were responsible for the selection of the published articles, concept of data analysis, data interpretation and revision of the manuscript.
There was no external funding related to this review.
Compliance with ethical standards
Conflict of interest
Teerachat Saeheng, Kesara Na-Bangchang and Juntra Karbwang have no conflicts of interest in this review.
- 12.Chen Y, Zhao K, Liu F, Xie Q, Zhong X, Miao X, Liu X, Liu L (2016) Prediction of deoxypodophyllotoxin disposition in mouse, rat, monkey, and dog by physiologically based pharmacokinetic model and the extrapolation to human. Front Pharmacol. https://doi.org/10.3389/fphar.2016.00488
- 13.Takahashi RH, Choo EF, Ma S, Wong S, Halladay J, Deng Y, Rooney I, Gates M, Hop CE, Khojasteh SC, Dresser MJ, Musib L (2016) Absorption, metabolism, excretion, and the contribution of intestinal metabolism to the oral disposition of [14C]cobimetinib, a MEK inhibitor, in humans. Drug Metab Dispos. https://doi.org/10.1124/dmd.115.066282 CrossRefGoogle Scholar
- 20.Diestelhorst C, Boos J, McCune JS, Russell J, Kangarloo SB, Hempel G (2013) Physiologically based pharmacokinetic modelling of busulfan: a new approach to describe and predict the pharmacokinetics in adults. Cancer Chemother Pharmacol. https://doi.org/10.1007/s00280-013-2275-x CrossRefGoogle Scholar
- 24.Tan W, Yamazaki S, Johnson TR, Wang R, O’Gorman MT, Kirkovsky L, Boutros T, Brega NM, Bello A (2017) Effects of renal function on crizotinib pharmacokinetics: dose recommendations for patients with ALK-positive non-small cell lung cancer. Clin Drug Investig. https://doi.org/10.1007/s40261-016-0490-z CrossRefGoogle Scholar
- 25.Lu C, Suri A, Shyu WC, Prakash S (2014) Assessment of cytochrome P450-mediated drug–drug interaction potential of orteronel and exposure changes in patients with renal impairment using physiologically based pharmacokinetic modeling and simulation. Biopharm Drug Dispos. https://doi.org/10.1002/bdd.1919 CrossRefGoogle Scholar
- 32.Filppula AM, Neuvonen M, Laitila J, Neuvonen PJ, Backman JT (2013) Autoinhibition of CYP3A4 leads to important role of CYP2C8 in imatinib metabolism: variability in CYP2C8 activity may alter plasma concentrations and response. Drug Metab Dispos. https://doi.org/10.1124/dmd.112.048017 CrossRefGoogle Scholar
- 33.Mao J, Johnson TR, Shen Z, Yamazaki S (2013) Prediction of crizotinib-midazolam interaction using the Simcyp population-based simulator: comparison of CYP3A time-dependent inhibition between human liver microsomes versus hepatocytes. Drug Metab Dispos. https://doi.org/10.1124/dmd.112.049114 CrossRefGoogle Scholar
- 34.Posada MM, Bacon JA, Schneck KB, Tirona RG, Kim RB, Higgins JW, Pak YA, Hall SD, Hillgren KM (2015) Prediction of renal transporter mediated drug-drug interactions for pemetrexed using physiologically based pharmacokinetic modeling. Drug Metab Dispos. https://doi.org/10.1124/dmd.114.059618 CrossRefGoogle Scholar
- 40.Dickschen K, Willmann S, Thelen K, Lippert J, Hempel G, Eissing T (2012) Physiologically based pharmacokinetic modeling of tamoxifen and its metabolites in women of different CYP2D6 phenotypes provides new insight into the tamoxifen mass balance. Front Pharmacol. https://doi.org/10.3389/fphar.2012.00092
- 44.Dickschen K, Eissing T, Mürdter T, Schwab M, Willmann S, Hempel G (2014) Concomitant use of tamoxifen and endoxifen in postmenopausal early breast cancer: prediction of plasma levels by physiologically-based pharmacokinetic modeling. Springerplus. https://doi.org/10.1186/2193-1801-3-285 CrossRefPubMedCentralGoogle Scholar
- 45.Budha NR, Ji T, Musib L, Eppler S, Dresser M, Chen Y, Jin JY (2016) Evaluation of cytochrome P450 3A4-mediated drug-drug interaction potential for cobimetinib using physiologically based pharmacokinetic modeling and simulation. Clin Pharmacokinet. https://doi.org/10.1007/s40262-016-0412-5 CrossRefGoogle Scholar
- 48.U.S. Food and Drug Administration (FDA) (2016) Physiologically based pharmacokinetic analyses-format and content guidance for industry. Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research at the Food and Drug Administration, Silver Spring. https://www.fda.gov/downloads/Drugs/GuidanceCOmplianceRegulatoryInformation/Guidances/UCM531207.pdf. Accessed 30 Dec 2016
- 49.European Medicine Agency (EMA) (2016) Guidance for quantification and reporting of physiologically based pharmacokinetic (PBPK) modelling and simulation (draft guidance). The committee for medicinal products for human use (CHMP). http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/clinical_pharmacology_pharmacokinetics/general_content_001729.jsp&mid=WC0b01ac0580032ec5. Accessed 30 Dec 2016
- 54.Sager JE, Yu J, Ragueneau-Majlessi I, Isoherranen N (2015) Physiologically based pharmacokinetic (PBPK) modeling and simulation approaches: A systematic review of published models, applications, and model verification. Drug Metab Dispos. https://doi.org/10.1124/dmd.115.065920 CrossRefPubMedCentralGoogle Scholar
- 56.Poulin P, Jones RD, Jones HM, Gibson CR, Rowland M, Chien JY, Ring BJ, Adkison KK, Ku MS, He H, Vuppugalla R, Marathe P, Fischer V, Dutta S, Sinha VK, Björnsson T, Lavé T, Yates JW (2011) PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approach. J Pharm Sci. https://doi.org/10.1002/jps.22550 CrossRefGoogle Scholar
- 64.Fearon KC, Preston T (1990) Body composition in cancer cachexia. Infusiontherapie 17(3):63–66Google Scholar
- 65.Cova D, Lorusso V, Silvestris N (2006) The pharmacokinetics and pharmacodynamics of drugs in elderly cachectic (Cancer) patients. In: Mantovani G, Anker SD, Inui A, Morley JE, Rossi Fanelli F, Scevola D, Schuster MW, Yeh S-S (eds) Cachexia and wasting: a modern approach. Springer, Milan, pp 377–382Google Scholar
- 67.European Medicine Agency (EMA), Committee for Medicinal Products for Human Use (CHMP) (2005) Guideline on the evaluation of the pharmacokinetics of medicinal products in patients with impaired hepatic function. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003122.pdf. Accessed 17 Mar 2017
- 68.European Medicine Agency (EMA), Committee for Medicinal Products for Human Use (CHMP) (2014) Guideline on the evaluation of the pharmacokinetics of medicinal products in patients with decreased renal function. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/02/WC500162133.pdf. Accessed 17 Mar 2017
- 69.Launay-Vacher V, Oudard S, Janus N, Gligorov J, Pourrat X, Morere JF RO, Beuzeboc P, Deray G, Renal Insufficiency and Cancer Medications (IRMA) Study Group (2007) Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study. Cancer. https://doi.org/10.1002/cncr.22904 CrossRefGoogle Scholar
- 71.Xiao JJ, Chen JS, Lum BL, Graham RA (2017) A survey of renal impairment pharmacokinetic studies for new oncology drug approvals in the USA from 2010 to early 2015: a focus on development strategies and future directions. Anti-Cancer Drugs. https://doi.org/10.1097/CAD.0000000000000513 CrossRefPubMedCentralGoogle Scholar